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Abstract
Robust cellular models are key in determining pathological mechanisms that lead 
to neurotoxicity in Huntington's disease (HD) and for high throughput pre-clinical 
screening of potential therapeutic compounds. Such models exist but mostly com-
prise non-human or non-neuronal cells that may not recapitulate the correct bio-
chemical milieu involved in pathology. We have developed a new human neuronal 
cell model of HD, using neural stem cells (ReNcell VM NSCs) stably transduced 
to express exon 1 huntingtin (HTT) fragments with variable length polyglutamine 
(polyQ) tracts. Using a system with matched expression levels of exon 1 HTT frag-
ments, we investigated the effect of increasing polyQ repeat length on HTT inclu-
sion formation, location, neuronal survival, and mitochondrial function with a view 
to creating an in vitro screening platform for therapeutic screening. We found that 
expression of exon 1 HTT fragments with longer polyQ tracts led to the formation 
of intra-nuclear inclusions in a polyQ length-dependent manner during neurogenesis. 
There was no overt effect on neuronal viability, but defects of mitochondrial func-
tion were found in the pathogenic lines. Thus, we have a human neuronal cell model 
of HD that may recapitulate some of the earliest stages of HD pathogenesis, namely 
inclusion formation and mitochondrial dysfunction.
K E Y W O R D S
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1 |  INTRODUCTION
Huntington's disease (HD) is an autosomal dominant in-
herited neurodegenerative disorder, typically of adult onset, 
with irreversible progression of motor, cognitive, and psy-
chiatric symptoms over 10-15 years.1 There are currently no 
disease-modifying therapies. The causative mutation is an 
expanded CAG repeat in exon 1 of the gene encoding the 
huntingtin protein (HTT), which leads to an elongated poly-
glutamine (polyQ) stretch within its N-terminal domain. The 
length of the CAG repeat is critical in determining disease 
status; inheritance of 36-39 CAG repeats leads to a reduced 
penetrance form of HD, whereas 40 or more CAGs causes 
the fully penetrant form. Longer repeat lengths are associated 
with an earlier age of onset and faster disease progression, 
with the inheritance of more than 55 CAGs leading to juve-
nile HD, in which age of onset occurs before 20 years of age.2
The “exon 1 fragment” of mutant HTT has long been postu-
lated as a key driver of neurotoxicity in HD. Histopathological 
studies of post-mortem human brains reveal that neuronal 
inclusions are recognized only by N-terminal HTT antibod-
ies.3,4 The R6/2 mouse that expresses a human exon 1 HTT 
transgene has the earliest onset and fastest progressing HD 
mouse phenotype and has been used extensively in HD re-
search.5 A study of N-terminal fragments in Drosophila has 
confirmed that exon 1 HTT is the most toxic HTT species.6 
Mutant exon 1 HTT fragments can be generated by an in-
complete splicing event resulting in a small exon 1 - intron 
1 polyadenylated transcript.7 This incompletely spliced tran-
script is present in all knock-in HD mouse models7 and HD 
post-mortem brains and fibroblasts,8 supporting a role in HD 
pathogenesis.
Over-expression of mutant exon 1 HTT demonstrates 
toxicity in multiple cell systems,9-11 but many such cell 
models are non-human and/or non-neuronal and degree of 
over-expression of exon 1 HTT is also often unquantified. 
The recent development of human embryonic and induced 
pluripotent stem cells has raised the possibility of their use 
in disease modelling and drug screening, but these models 
are less amenable to high throughput formats and interpreta-
tion of data is frequently confounded by the genetic variabil-
ity between lines and lack of isogenic controls.12 Therefore, 
we chose to engineer ReNcell VM human neural stem cells 
(NSCs)13 to stably express exon 1 HTT fragments with vary-
ing polyQ-length expansions at relatively matched expression 
levels upon an isogenic background. ReNcell VM NSCs rap-
idly differentiate into a high proportion of midbrain GABA-
ergic neurons13,14; transduced NSCs maintained exogenous 
exon 1 HTT expression following differentiation, whilst a 
small proportion of cells developed mutant HTT-positive 
inclusions. High content imaging of this new cell model of 
HD was carried out using the PerkinElmer Opera platform 
and mitochondrial respiratory chain function was assessed 
using the Seahorse XFe96 Analyzer and spectrophotometric 
enzyme assays. This enabled the study of the effect of mutant 
exon 1 HTT on differentiation and cell metabolism during the 
switch from NSC to neuronal fate and allowed the evaluation 
of this model for high throughput drug screening.
2 |  MATERIALS AND METHODS
All reagents obtained from Sigma or Thermo Fisher Scientific 
unless otherwise stated.
2.1 | ReNcell VM cell culture
The ReNcell VM NSC line was obtained from ReNeuron. 
NSCs were grown as a monolayer on Nunc plasticware pre-
coated with laminin [Cultrex mouse laminin I, PathClear, 
AMS Biotechnology] pre-diluted 20  µg/mL in cold 
DMEM-F12 medium. NSC medium comprised Dulbecco's 
Modified Eagle's Medium (DMEM): Nutrient Mixture F-12 
(F12) supplemented with: 0.03% of human albumin solution, 
5  µg/mL of transferrin (human recombinant), 16.2  µg/mL 
of putrescine dihydrochloride, 5  μg/mL of insulin (human 
recombinant), 400  ng/mL of l-thyroxine, 337  ng/mL of 
tri-iodo-thyronine, 60  ng/mL of progesterone, 2mM l-glu-
tamine, 40 ng/mL of sodium selenite, 10 Units/mL of heparin 
sodium, 10 ng/mL of corticosterone, 10 ng/mL of basic fibro-
blast growth factor [bFGF, Peprotech], and 20 ng/mL of epi-
dermal growth factor [EGF, Peprotech]. NSCs required a full 
media change every 3-4 days and were passaged at 80%-90% 
confluency. To passage, cells were washed with Hank's bal-
anced salt solution (HBSS) and trypsinized using Trypzean-
EDTA [Lonza] that was added in sufficient volume to coat 
the surface of the flask and incubated at 37°C; 5% of CO2 for 
5 minutes. An equivalent volume of defined trypsin inhibitor 
(DTI) was added to the flask, and the cells were triturated and 
transferred to a Falcon tube for centrifugation at 350 g for 
5 minutes at room temperature. The resulting cell pellet was 
re-suspended in warm NSC medium prior to re-seeding at a 
density of 1.2 × 104 cells/cm2. On reaching 90% confluency, 
ReNcell VM NSCs were switched into differentiation me-
dium (NSC medium without the addition of bFGF and EGF, 
and supplemented with 2 ng/mL of glial cell-derived neuro-
trophic factor [GDNF, Peprotech] and 0.5 mM of dibutyryl 
cyclic adenosine monophosphate [dbcAMP, Calbiochem]). 
Differentiating cell cultures had a full media change every 
3-4 days. After two weeks, the differentiation medium was 
no longer supplemented with GDNF or dbcAMP, and a lower 
l-glutamine concentration of 0.5  mM was used. ReNcell 
VM neurons were maintained in this long-term differentia-
tion media for up to six weeks, with media changes every 
3-4 days. DD stands for day of differentiation.
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2.2 | Generation of exon 1 HTT expressing 
ReNcell VM NSCs
ReNcell VM NSCs underwent lentiviral transduction with 
vectors containing HTT exon 1 with 30, 71, and 122 CAG 
repeats, respectively, each linked with an internal ribosome 
entry site (IRES) to the gene encoding green fluorescent 
protein (GFP) (Figure S1A). Sanger sequencing of the con-
structs was performed to verify sequence fidelity. The HTT 
exon 1 122 CAG stretch contains a CAA interruption at the 
ninth penultimate codon. The internal ribosome entry site 
(IRES) sequence allows translation initiation in the mid-
dle of an mRNA, allowing for the independent translation 
of HTT exon 1 and GFP. The A2UCOE promoter reduces 
the chance of post-integration transgene silencing by confer-
ring a dominant chromatin opening function, which is a more 
transcriptionally active structure.15 The woodchuck post-
transcriptional regulatory element (WPRE) is commonly in-
serted into lentiviral constructs to increase mRNA transport 
out of the nucleus, hence increasing viral titre. To create a 
negative control line, ReNcell VM NSCs were transduced 
with a GFP-only expressing vector.
For each line, the cells were sorted by fluorescence-ac-
tivated cell sorting (FACS) on the basis of GFP expression. 
Four populations of low to high expressing cells were ob-
tained for each line. Our aim was to find a panel of cell lines 
with similar expression levels of exon 1 HTT to control for 
potential expression-dependent effects of the peptide on 
cellular phenotype as opposed to increasing polyQ-repeat 
length. We chose the lowest expressing lines, which were also 
most equally matched for protein expression, to use in these 
experiments. We used a higher expressing 71 CAG line as 
a positive control (71 CAG-H) and the non-transduced wild 
type ReNcell VM line in some experiments.
2.3 | Protein detection
Western blotting was carried out using the Li-Cor system. 
A methanol precipitation step was included in the prepara-
tion of samples for blotting with anti-HTT antibodies and 
cell markers. Samples (20  µg protein/sample) were loaded 
onto Novex 12% of Tris-Glycine gel (or 8% where stated), 
with 60-90  minutes run time at 150  V, followed by over-
night transfer step at 15 V. Antibodies used to detect HTT 
were S830, raised against the product of the N-terminal re-
gion to 53 glutamine residues (sheep, 1:200016) and 4C9; 
raised against HTT residues 65-84 (mouse, 1:1000, CHDI 
Foundation). Other antibodies included anti-βIII-tubulin (rab-
bit, 1:5000, Abcam), anti-GAPDH (rabbit, 1:10 000, Merck 
or 1:2500, Abcam), and anti-nestin MAB5326 (mouse, 
1:5000, Millipore). To examine mitochondrial function, we 
carried out Western blotting for complex subunits NDUFB8 
(complex I), SDHB (complex II), UQCRC2 (complex III), 
MTCO1 (complex IV), and ATP5A (complex V) using 
the Total OXPHOS rodent WB antibody cocktail at 1:250 
(Abcam). To quantify OPA-1 isoforms, anti-OPA-1 antibody 
(mouse, 1:1000, BD Biosciences) was used. Cell pellets were 
lysed using RIPA buffer containing complete protease in-
hibitors and PhosSTOP phosphatase inhibitors (Roche) and 
28 U/mL of benzonase. Gel samples were run out on BOLT 
4%-12% of Bis-Tris Plus gels (Thermo Fisher Scientific) 
using either MES (OXPHOS) or MOPS (OPA-1) SDS run-
ning buffers. For OXPHOS detection PVDF was used, for 
all other antibodies nitrocellulose membrane was used. Li-
Cor detection was used to detect bands and densitometry per-
formed using the Image Studio 5.2 software (Li-Cor).
Cell pellets of each line were made for quantification of 
total and mutant HTT levels using the Meso Scale Diagnostics 
ELISA-based electrochemiluminescence platform.17 The 
2B7/4C9 antibody pair was used to detect total HTT and 2B7/
MW1 antibody pair was used to detect mutant HTT.
2.4 | Immunofluorescence
Cells were fixed with 4% of paraformaldehyde for 20 min-
utes at room temperature, and then, washed gently with PBS. 
Cells were then permeabilized with 0.2% of Triton X-100 for 
15 minutes at room temperature. Blocking was performed by 
applying 10% of donkey serum diluted in PBS for 1 hour at 
room temperature. The blocking buffer was removed and pri-
mary antibodies pre-diluted in PBS were applied to cells prior 
to incubation overnight at 4°C. The primary antibodies used 
were S830 (sheep, 1:500), EM48 (mouse, Millipore; 1:100), 
anti-βIII-tubulin (rabbit, 1:500, Abcam), and anti-activated 
caspase-3 (rabbit, 1:100, Abcam). The monoclonal antibod-
ies PHP1 and PHP2 (1:1000), raised against the proline-rich 
domain (PRD) of HTT were a kind gift from Professor A. 
Khoshnan.18 After five washes in PBS, secondary antibodies 
were added at a dilution of 1:1000 and incubated for 1 hour 
in the dark at room temperature. After two further wash steps 
Hoescht diluted 1 µg/mL in PBS was added for 5 minutes at 
room temperature. Cells were washed thrice more and stored 
in PBS containing sodium azide (0.02%) at 4°C in the dark 
until imaged.
2.5 | High content imaging
CellCarrier96 plates [Perkin Elmer] were pre-coated with 
laminin and seeded with exon 1 HTT over-expressing 
ReNcell VM NSCs at a density of 25 000 cells/well. After 
24 hours differentiation was initiated. Plates were fixed and 
stained at various time-points as described. Image capture for 
high content imaging was carried out using the PerkinElmer 
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Opera LX or Opera Phenix HCS system using a 40× air NA 
0.6 objective, with 15-18 fields of view captured per well. 
Channels for Hoechst, 488, 568, and 647 were selected, the 
power set to 100% and separated, where appropriate to pre-
vent cross-talk. Heights for imaging were kept constant for 
each channel and each antibody combination, as crucially, 
were the gain settings.
2.6 | Image analysis and 
statistical evaluation
Image analysis was performed using ImageJ19 version 1.50c 
(IJ) running under Linux on a Tyan FT48-B8812 High 
Performance Barebone System equipped with 256GB RAM 
memory. The open source R software20 version 3.2.2 was 
used for statistical analysis. The results of this are shown in 
Figure 3. Median of the maximum pixel intensity of nuclei 
per well (Median I-max) was calculated as the following: 
Nuclear channel images were processed with noise reduction 
by applying a 3 pixel radius median filter followed by seg-
mentation using intensity threshold value 144, which was cal-
culated by applying an Otsu segmentation algorithm on the 
whole stack of images. Subsequently, a watershed filter was 
used to separate merged nuclei. The total cell count (tot cells) 
in each image was calculated from the result and maximum 
intensity on channel 2 was calculated under the area of each 
nucleus object. The median of those maximum values was 
calculated for each well. The total number of aggregate con-
taining nuclei as a proportion of the total cell count (percent-
age abnormal cells as determined by the total nuclear count) 
was calculated, where aggregate containing nuclei was de-
fined as nuclei with maximum intensity on ch2 > 2000.
Total number of nuclear aggregates (NAs) per aggregate 
containing nucleus (ACN, No. NAs per ACN) was calculated 
with watershed segmentation IJ Find Maxima algorithm using 
noise parameter 150. Mean background intensity after all ag-
gregates have been removed from the field of view (Mean 
background) was calculated by segmenting channel 2 images 
with threshold value 2000 and calculate the mean intensity 
of pixels less than intensity 2000. Extra-nuclear aggregate 
(ENA) count per field of view divided by the total cell count 
in that field of view (ENAs/tot cells) was calculated using 
watershed segmentation IJ Find Maxima algorithm with 
noise parameter 150 applied outside the area of nuclear mask 
in each image. Total number of aggregates (both intra- and 
extra-nuclear) per field of view divided by the total cell count 
in that given field of view (tot aggs/tot cells). Where total 
number of aggregates was calculated with watershed seg-
mentation IJ Find Maxima algorithm using noise parameter 
1000. Total number of nuclear aggregates only per field of 
view divided by the total cell count in that given field of view 
(NAs/tot cells) was calculated by the ratio of No. NAs per 
ACN and tot cells as described above. Total area of nuclear 
aggregates divided by total nuclear area (NA area/tot nuclear 
area) was calculated by segmenting the channel 2 area under 
nuclei with intensity maximum > 2000 with a thresholding 
value of 969, which resulted in the area of nuclear aggregates 
in a given nucleus. The total nuclear area was used to calcu-
late this ratio.
Images captured by the Opera Phenix were analyzed using 
Perkin Elmer Columbus v. 2.8.0 image analysis software. In 
summary, individual planes were analyzed (without flatfield 
correction). Nuclei were identified using the software's Find 
Nuclei function and the area, intensity, and roundness of 
Hoechst staining was measured. The total nuclear count was 
used as a surrogate marker for the total cell count in each 
image. βIII-tubulin + cells were detected and counted using 
the Find Cytoplasm function, the mean intensity of staining 
measured and the neuronal population selected by threshold-
ing on mean intensity. Nuclear inclusion bodies (IB) were 
identified using the Find Spots function using Method B (de-
tection sensitivity 0.1, splitting co-efficient 0.5). Appropriate 
population outputs and formula outputs were selected for 
Define Results, and the data downloaded and exported for 
statistical analysis using GraphPad Prism 6. Data were ana-
lyzed as the mean of one well of each cell line and condition, 
subject to one-way or two-way ANOVA with Bonferroni's 
correction. A 95% confidence interval (P < .05) was consid-
ered a statistically significant observation. The results of this 
are shown in Figures 1B,C, 2D, and 4B.
2.7 | Structured illumination microscopy
Super resolution fluorescent images were captured using a 
Nikon Eclipse Ni-E N- SIM Super Resolution system and 
Andor Ixon camera. Images were saved as ND2 files and pro-
cessed using NIS Elements AR software with n-SIM module. 
Final images were exported as TIFF file images. Acquisition 
was performed in a 3D SIM mode using the 100 × 1.49 NA 
total internal reflection fluorescence objective lens with 28 z 
steps per stack at a step interval of 0.1 µm.
2.8 | Viability and ATP assays
Clear plastic 96 well plates [Nunc] were pre-coated with 
laminin and seeded with exon 1 HTT expressing ReNcell 
VM NSCs at a density of 25 000 cells/well. After 24 hours 
differentiation was initiated. Cell death and viability of 
cultures was assessed at regular time points using a lactate 
dehydrogenase (LDH) release assay (CytoTox 96 Non-
Radioactive Cytotoxicity Assay [Promega]) or MTT assay 
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(In Vitro Toxicology Assay Kit, MTT based [Merck]) as per 
the manufacturer's instructions. ATP levels were quantified 
using Promega's CellTiter-Glo 2.0 Assay according to the 
manufacturer's instructions, using six biological replicates 
per experimental line/condition. For NSCs, cells were disso-
ciated using Accutase (Thermo Fisher Scientific) and 27 000 
cells/reaction were used. Neurons cultured in 96 well plates 
were first dissociated by incubating in 100 µL/well Accutase 
for 15 minutes, then, gently dissociating by trituration. Next, 
90  µL of this was added to the 1× reaction mixture, and 
10 µL used to count cells. Luminescence readings per well 
were then normalized to input cell number. CoQ10 used in 
supplementation experiments was purchased from Sigma and 
dissolved in ethanol.
2.9 | Seahorse XFe96 bioanalyser
NSCs were plated into laminin-coated (20 µg/mL) Seahorse 
XF Cell Culture PS Microplates (Agilent) at 30,000 per well 
in NSC medium. NSC measurements were performed the 
following day. For neuronal measurements, the cells were 
switched into 200 µL differentiation medium per well after 
24 hours. After 5 days differentiation, all media was removed 
and replaced a final time with fresh differentiation medium. 
The Seahorse XF Cell Mito Stress Test was performed 
at DD7 due to the fragility of the neurons in this assay at 
DD14. Seahorse Bioanalyser XFe96 assays were carried out 
according to the manufacturer's instructions (Agilent). The 
XF assay medium was made up by supplementing XF base 
F I G U R E  1  Differentiation of ReNcell VM exon 1 HTT expressing human midbrain NSCs to GABAergic neurons. A, ReNcell VM NSCs 
that express exon 1 HTT and GFP, as well as GFP-only cells were differentiated to DD14. Immunofluorescence imaging revealed these cells have 
a neuronal morphology and express βIII-tubulin (red, nuclei blue). B, Analysis of βIII-tubulin staining intensity following high content imaging 
showed a small but significant decrease in the 122 CAG line compared to the control GFP-only and 30 CAG lines; one-way ANOVA with 
Bonferroni's correction, (n = 8 wells, *P < .05, ***P < .001, ns - not significant). C, Analysis of nuclear metrics using Columbus software showed 
no significant differences in mean nuclear area, nuclear staining intensity or roundness between any of the lines (values normalized to those of the 
GFP line); one-way ANOVA with Bonferroni's correction (n = 80 wells). Data are shown as mean ± SEM
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medium (Agilent) with 10 mM of d-glucose, 2 mM of glu-
tamine, 1 mM of sodium pyruvate, and adjusted to pH 7.4. 
The neurons were washed gently twice with warm XF assay 
medium before replacing with 175 µL final volume medium. 
Cells were equilibrated prior to the assay by placing in a 
37°C CO2-free incubator for 20 minutes. The test compound 
concentrations were determined by separate optimization 
experiments for either NSCs or neurons and set as follows: 
Oligomycin (1.0 µM), FCCP (2 µM for NSCs, 0.2 µM for 
neurons), and rotenone/antimycin A (2 µM). For more robust 
NSC assays, the assay cycles were set at mix 40  seconds, 
wait 30  seconds, measure 2  minutes. For the more fragile 
neurons, the assay cycles were set at mix 10 seconds, wait 
30 seconds, measure 2 minutes. Following each assay, mi-
croplates were retained, and cells fixed with 10% of formalin 
(Sigma) at room temperature for 15  minutes, before stain-
ing with DAPI and imaging on a MetaXpress plate reader. 
Mean cell densities/well were calculated using ImageXpress 
and each well density was normalized to the lowest density 
value. Individual well OCR measurements (pmol/min) for 
each time point were then divided through by the normalized 
well cell density value for that well, using the normalization 
function of the Seahorse Wave Desktop software (Agilent). 
Respiratory parameters were calculated using this software, 
as per the manufacturer's instructions. Non-mitochondrial 
respiration  =  (minimum rate measurement after rotenone/
antimycin A injection), basal respiration =  (last rate meas-
urement before first injection)  −  (non-mitochondrial respi-
ration), maximal respiration = (maximum rate measurement 
after FCCP injection)  −  (non-mitochondrial respiration), 
proton leak = (minimum rate measurement after oligomycin 
injection)  −  (non-mitochondrial respiration), ATP produc-
tion =  (last rate before oligomycin injection) −  (minimum 
rate measurement after oligomycin injection), coupling ef-
ficiency = (ATP production rate)/(basal respiration) × 100. 
Mean parameters for each line were calculated from 10 tech-
nical replicates and further normalized as a percentage of 
the 30 CAG line mean. In initial experiments, the 30 CAG 
line was found to be phenotypically indistinguishable from 
the GFP only line so 30 CAG was used as the experimen-
tal control line for these assays. The assays were repeated 
three times and data compared using one-way ANOVA with 
Tukey's multiple parameter test.
2.10 | Mitochondrial respiratory 
chain activity
Activities of respiratory chain complex I ([NADH dehydro-
genase, EC 1.6.5.3]; nmol/min/mg total protein), complex 
II  +  III ([succinate: cytochrome c reductase]; nmol/min/
mg total protein), complex IV ([cytochrome c oxidase: EC 
1.9.3.1]; k/min/mg total protein), and citrate synthase ([CS, 
EC 2.3.3.1]; nmol/min/mg total protein) were determined 
in the differentiated ReNcell VM neurons as previously de-
scribed.21 The principal of the complex II  +  III assay is 
that succinate is oxidized by complex II and these electrons 
are then transferred from complex II to complex III by en-
dogenous CoQ10. These electrons can be used by complex 
III to reduce oxidized cytochrome c. In the assay, complex 
II  +  III activity is then measured by the succinate-depend-
ent antimycin A-sensitive reduction of cytochrome c, which 
is followed at 550  nm according to the method of King.22 
Statistical analysis: Repeated measures ANOVA with Tukey 
post hoc test. Complex II activity assay was modified from 
Hatefi and Stiggall.23 Complex II-specific activity (nmol/
min/mg total protein) was measured at 30°C following the 
reduction of 2,6-dichloroindophenol (DCPIP) at 600  nm 
(molar ε  =  21  000  M-1  cm−1). Cellular homogenates were 
pre-incubated for 10 minutes a cuvette containing 50 mM of 
potassium phosphate buffer pH 7.4, 20 mM of sodium succi-
nate, 0.1 mM of di-potassium EDTA, 74 µM of DCPIP, 1 mM 
of potassium cyanide, 10 µM of rotenone. The reaction was 
started with 50 µM of ubiquinone. The reaction was monitored 
for 5 minutes after which 1 mM of 2-thenoyltrifluoroacetone 
(TTFA) to the cuvette and the reaction monitored for a further 
10 minutes. The enzyme rate was determined to be the TTFA 
sensitive reduction of DCPIP. Complex III activity assay was 
modified from Kirby et al.24 Complex III-specific activity (k/
min/mg total protein) was measured at 30°C following the 
reduction of cytochrome c using ubiquinol-2 as the electron 
donor and monitoring the increase in reduced cytochrome c at 
550 nm (molar ε = 19.2 M−1 cm−1). A 1 mL cuvette contain-
ing 35 mM of potassium phosphate buffer pH 7.2, 5 mM of 
magnesium chloride, 1 mM of di-potassium EDTA, pH 7.2, 
2 mM of potassium cyanide, 15 µM of cytochrome c, 5 µM 
of rotenone was pre-incubated for 2 minutes. Non-enzymatic 
reduction of cytochrome c was initiated with the addition 
of 15 µM of ubiquinol-2 and monitored for 2 minutes, after 
which cellular homogenate was added and the reaction moni-
tored for 2 minutes. As the enzyme reaction rate is non-linear, 
activity was expressed as pseudo first order rate constant k 
after subtraction of the non-enzymatic rate. The CoQ10 status 
(pmol/mg total protein) of cell samples was determined by 
reverse phase HPLC with UV detection at 275 nm according 
to the method of Duncan et al, 2005.25 Readouts are calculated 
as ratios of complex activity:CS activity or CoQ10 status:CS 
activity to account for variation in mitochondrial content.26 
Statistical analyses: Student's t test between three independent 
30 CAG and 122 CAG DD14 neuronal cultures.
2.11 | TMRM and volumetric analysis
Basal mitochondrial membrane potential was analyzed 
using TMRM as described previously.14 Individual 
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TMRM  +  mitochondria detected within cells using Image 
J were classified as small (<100  µm3), medium (100-
1000  µm3), or large (>1000  µm3), and the sum of all mi-
tochondrial volumes within each category expressed as a 
percentage of total mitochondrial volume.
3 |  RESULTS
3.1 | Generation of NSCs expressing exon 1 
HTT with increasing CAG repeat lengths
ReNcell VM NSCs were transduced with lentiviral vectors 
containing HTT exon 1 with pathological 71 and 122 CAG 
repeats, and also a non-pathological 30 CAG repeat length, 
each linked with an internal ribosome entry site (IRES) to 
the gene encoding GFP (Figure S1A). To create a negative 
control line, ReNcell VM NSCs were transduced with a 
GFP-only expressing vector. The cells were then sorted by 
FACS on the basis of GFP expression, creating populations 
of cells with equivalent expression levels. The GFP expres-
sion in the NSCs is shown in Figure S1D. Expression of 
exon 1 HTT was confirmed in NSCs and differentiated 
neurons and precise protein levels were quantified using a 
Meso Scale Diagnostics ELISA-based assay with 2B7 and 
4C9 anti-HTT antibodies (Figure  S1B). Western blotting 
cell lysates from each line using S830 and 4C9 antibodies 
confirmed robust expression of exon 1 HTT (Figure S1C). 
Each CAG repeat sequence is followed by CAA CAG co-
dons that are also translated as glutamine (Q) residues; 
thus, an allelic series with closely matched, relatively low 
expression levels of 32Q, 73Q, and 124Q exon 1 HTT was 
established.
3.2 | Neural stem cells expressing exon 1 
HTT can be differentiated into neurons that 
develop intra- and extra- nuclear inclusions
The ReNCell line expresses relevant neuronal markers fol-
lowing differentiation, including βIII-tubulin, MAP2, GABA, 
tau proteins, and others.13,14,27 Upon initiation of differentia-
tion and subsequent culture for fourteen days (DD14), the 
ReNcell VM exon 1 HTT lines also generated a high propor-
tion of neurons, confirmed using immunofluorescence and 
Western blotting with anti-βIII-tubulin antibodies (Figure 1A 
and Figure S2A). Quantification of images using high vol-
ume image data analysis software (PerkinElmer Columbus) 
confirmed that 96%-97% of cells expressed the neuronal 
marker βIII-tubulin, except for the 122 CAG line, which had 
a slightly lower proportion at 94% (Figure 1B). However, no 
significant difference in overall βIII-tubulin protein level was 
observed in this line by Western blotting (Figure  S2B,C). 
Analysis of nuclear metrics by immunofluorescence (mean 
area, intensity of Hoechst staining, and roundness) across 
the panel of cells showed no differences between the lines 
(Figure 1C).
We did not detect extra- or intra nuclear HTT inclusions 
in NSCs in any lines (Figure 2A). However, following dif-
ferentiation to neuronal cultures (DD14), the pathogenic 
lines (71 CAG and 122 CAG) were found to harbour in-
tra-nuclear IBs and a small number of extra-nuclear IBs, 
as detected by immunofluorescence (Figure  2A). These 
inclusions were found to stain with the polyclonal S830 
and monoclonal EM48, PHP1, and PHP2 anti-HTT anti-
bodies (Figure 2B and Figure S2D). IBs were not present 
in the GFP only control or 30 CAG line. Western blot-
ting using the same antibodies detected high molecular 
weight bands retained within the stacking gel following 
SDS-PAGE; confirming the presence of insoluble forms 
of mutant HTT exon 1 in the 71 and 122 CAG lines only 
(Figure  S1C). Interestingly, we observed that cells con-
taining IBs appeared to have lower or absent βIII-tubulin 
staining (Figure 2C); quantification of this using Columbus 
software confirmed that there was a significant reduction 
in the perinuclear cytoplasmic staining intensity, where IBs 
were present (Figure 2D).
3.3 | Inclusion body formation increases 
over time and displays CAG repeat-
length dependence
Using Image J, we were able to employ high throughput 
analysis techniques to quantify the intra-nuclear S830-
positive IBs and diffuse cytoplasmic staining observed in 
our images (Figure  S2E). We were unable to accurately 
quantify extra-nuclear IBs using Image J and R due to their 
paucity and small size. Significant CAG repeat length-
dependent differences in the percentage of IB-containing 
nuclei appeared over time (Figure 3A), with no significant 
change in total cell count over time (Figure  S3A). The 
number of inclusions per inclusion-containing nucleus also 
increased on differentiation and was CAG-repeat length 
dependent (Figure 3B). We also detected diffuse cytoplas-
mic S830 staining in the exon 1 HTT lines, which increased 
with time above background levels in the 71 and 122 CAG 
lines (Figure 3C).
We further explored IB formation using structured il-
lumination microscopy (SIM), with a resolution of 100-
120 nm. This revealed multiple smaller nuclear inclusions 
previously unseen with standard confocal microscopy 
(Figure 4A). We also observed the fine diffuse granular cy-
toplasmic staining of S830. No nuclear or cytoplasmic S830 
staining at all was detected in GFP-only cells suggesting 
this is not a staining artefact. Overall, nuclear morphology 
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was not observed to be compromised by the presence of in-
clusions, and the presence of nuclear IBs did not coincide 
with nuclear fragmentation or condensation that would be 
indicative of cell death. However, upon quantification, we 
found that mean nuclear size was significantly increased in 
IB containing cells compared to non-IB containing cells 
(Figure  4B). Unfortunately, due to the overlapping and 
complex nature of neuronal cultures, it was impossible to 
assess whether IB-containing neurons had also an increased 
overall cell size.
3.4 | Mutant exon 1 HTT expression has no 
effect on baseline cell viability
We assessed potential pathology-associated differences 
in baseline viability in the exon 1 HTT ReNcell VM panel 
by performing LDH assays at weekly intervals from DD0 - 
DD42. This finding was also confirmed using MTT assay, 
as well as immunofluorescence staining using anti-activated 
caspase 3 antibody. No significant differences in baseline vi-
ability between the lines were observed (Figure S3).
F I G U R E  2  Appearance of mutant HTT inclusions in ReNcell VM exon 1 HTT expressing neurons. A, The exon 1 HTT ReNcell VM lines 
did not display IB formation in the neural stem cell state. On differentiation to DD14, IBs appeared in the 71 CAG and 122 CAG lines. Intranuclear 
inclusions shown with yellow arrows, extranuclear inclusions indicated with orange arrows. B, The 71 CAG line with IBs that co-stain with 
anti-aggregated HTT antibodies S830 (green) and EM48 (red). GFP is shown in white. C, Nuclei that contained inclusions had reduced staining 
intensity in the cytoplasm, an example of which has been enlarged (red - βIII-tubulin; white - anti-HTT antibody S830; blue - nuclei). Scale 
bars = 20 µm. D, Quantification of this phenomenon confirmed that mean βIII-tubulin intensity in IB-containing cells was significantly less than in 
non-IB containing cells (n = 32 wells, **P < .01). Data are shown as mean ± SEM
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3.5 | Mutant exon 1 HTT expression causes 
respiratory chain deficits
Despite no overt loss of viability, oxidative metabolism was 
significantly altered in a CAG length-dependent manner 
in NSCs and young neurons (at DD7) as measured using a 
Seahorse XF Cell Mito Stress Test assay. There was a pro-
found reduction in basal respiration in the 122 CAG line even 
at the NSC stage and a trend to worsening of basal respira-
tion in the 71 CAG line following differentiation and the ap-
pearance of mutant HTT inclusions (Figure 5A). Crucially, 
ATP production - inferred from the oligomycin-sensitive 
component of OCR - was significantly reduced in  the 122 
CAG line at both developmental stages, implicating a re-
duction in basal ATP production in the presence of mutant 
exon 1 HTT (Figure 5B). This reduction in total ATP levels 
was confirmed in 30 CAG and 122 CAG NSCs and neurons 
using the microplate CellTiter-Glo 2.0 Assay (Figure S4A). 
In addition, a significant decrease in maximal respiration rate 
- assessed by the addition of the de-coupler FCCP - was ob-
served in the 122 CAG line (Figure 5C) in NSCs but not fol-
lowing differentiation. This corrective phenotype was seen 
in the non-mitochondrial component of OCR, which is the 
minor proportion of oxygen consumption attributable to non-
ETC enzymes. The same phenomenon was observed with 
proton leak, which can be a sign of mitochondrial damage; 
although significantly altered in the 122 CAG line NSCs, this 
was not impaired in neurons (Figure 5D,E). There were no 
differences in coupling efficiency between the lines in either 
their NSC or neuronal state (Figure 5F).
To examine the underlying mechanism for the respiratory 
impairments observed in neurons, we assessed the specific 
in vitro activities of electron chain components using spec-
trophotometric enzyme assays. Corresponding impairment in 
the specific activities complex I and II + III but not in complex 
IV in 122 CAG lines were observed when comparing across 
the whole panel of exon 1 HTT lines at DD14 (Figure 6A), 
in line with many previous reports.28 Upon finding a deficit 
in complex II +  III activity, we devised assays to measure 
complex II and III individually, as well as total CoQ10 status, 
which is required for complex II +  III activity.29 We com-
pared 30 CAG vs 122 CAG neurons and found that although 
complex II activity did not differ between the lines, complex 
III activity was significantly reduced in the 122 CAG neuro-
nal samples (Figure 6A). We found no decrease in the levels 
of total CoQ10 between the lines, suggesting that complex III 
F I G U R E  3  Accumulation of HTT inclusion bodies in ReNcell VM neurons in a time and exon 1 HTT CAG-dependent manner. High 
content imaging of the ReNcell VM exon 1 HTT lines at different stages of differentiation revealed that: A, The percentage of cells with nuclear 
IBs was CAG-length-dependent, with nuclear IBs appearing only in the 71 CAG and 122 CAG lines after DD7. B, The number of inclusions per 
inclusion containing nucleus was also CAG-length-dependent. C, The diffuse cytoplasmic anti-HTT (S830) antibody staining also increases over 
time compared with non-HD lines. Data are shown as mean ± SEM. Corresponding significance levels calculated using two-way ANOVA with 
Bonferroni's correction are shown below each graph (n = 16 wells per line)
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activity was not being compromised by reduced CoQ10 avail-
ability (Figure 6B).
We wished to examine whether this activity impairment 
was caused by a reduction in complex expression, so per-
formed Western blots using antibodies against complex sub-
units NDUFB8 (complex I), SDHB (complex II), UQCRC2 
(complex III), MTCO1 (complex IV), and ATP5A (complex 
V) (Figure 6C). These subunits were chosen because they are 
labile when not assembled within a complex, therefore, can 
be used as a proxy readout of expression for each complex. 
No significant differences were found in the expression of any 
of these subunits, when normalized to GAPDH (Figure 6D), 
suggesting that impairment in complex I and III activity is 
not caused by reduced expression of these complexes. To in-
vestigate a potential link between mitochondrial respiratory 
dysfunction and intranuclear mHTT IB formation in our 122 
CAG neurons, we increased endogenous ATP levels by sup-
plementing differentiating neurons with 5 µm CoQ1030 in the 
culture medium from DD7. Interestingly, this had no impact 
on the frequency of nuclei containing S830 + IBs by DD14 
(Figure S4B), suggesting that restoring ATP production does 
not directly affect IB formation.
We next assessed a potential knock-on effect of reduced 
ETC activity to basal mitochondrial potential (Ψm) by mea-
suring uptake of the membrane potential-dependent cationic 
dye, TMRM (Figure 7A,B and Figure S5A). Surprisingly this 
was not compromised in the HD lines; in fact there was a 
trend to increased mean TMRM intensity in the line showing 
respiratory impairment, suggesting a compensatory reversal 
of the ATP-synthase (complex V) observed in other models 
and thought to prevent Ψm collapse by reversing the pump-
ing of H  +  ions.31 TMRM imaging also revealed potential 
differences in mitochondrial morphology in the HD lines; 
whereas the 30 CAG and GFP only (not shown) lines had 
well-distributed, filamentous mitochondria, the 71 and 122 
CAG neurons contained mitochondria that were irregularly 
distributed, clumped or enlarged (Figure  7A, arrows). To 
attempt to quantify this objectively, we compared the indi-
vidual volumes of TMRM positive organelles generated as 
part of the TMRM assay. The sizes of mitochondrial puncta 
varied from ~1 to >1000 µm3 and we analyzed the relative 
proportions of mitochondria with different volumes within 
the exon 1 HTT lines (Figure 7C). Specifically, there was an 
increase in the percentage of total mitochondrial volume that 
F I G U R E  4  Structured illumination microscopy images of ReNcell VM exon 1 HTT neurons. A, Super-resolution images of fixed and stained 
122 CAG ReNcell VM neurons demonstrated that multiple smaller nuclear inclusions not previously seen with standard confocal microscopy can 
be seen. The GFP only line had no detectable S830 staining. Blue - Hoescht; red - anti-HTT antibody S830. Scale bars = 5 µm. B, Quantification 
of nuclear area from differentiated cultures showed mean nuclear area is greater in cells containing IBs. Data are shown as mean ± SEM. Statistics: 
one-way ANOVA with Bonferroni's correction. (n = 32 wells, *P < .05, **P < .01, ***P < .001)
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was comprised of medium size mitochondria (100-1000 µm3) 
in the 122 CAG neurons, compared to the 71 CAG by one-
way ANOVA (P = .0363). We speculated that there may be 
an imbalance in the fusion-fission processes caused by exon 1 
HTT expression. Therefore, Western blotting was performed 
on the control (30 CAG) vs longest length 122 CAG neuronal 
samples to quantify levels of the pro-fusion GTPase OPA1 
(Figure S5B). We found that the expression of the short form, 
long form, total or the ratio of long/short form of OPA1, al-
though trending towards an increase in the 122 CAG neurons, 
were not significantly different (Figure 7D).
4 |  DISCUSSION
We have generated a human neural stem cell line that ex-
presses exon 1 HTT with 30, 71, and 122 CAGs at relatively 
matched expression levels on an isogenic background, as 
well as a negative control line expressing only GFP. This 
allelic series generates cultures containing a very high 
proportion of βIII-tubulin positive neurons after a simple 
two-week differentiation protocol. In contrast to some other 
cells lines that express mutant exon 1 HTT, these lines do not 
show any overt cell death or toxicity at up to six weeks in 
culture, though there is a possible subtle deficit in neuronal 
differentiation in the 122 CAG line. They do show, however, 
CAG-length dependent, “pre-pathological” changes in terms 
of IB formation, increased nuclear size, and mitochondrial 
dysfunction. These cellular changes may reflect some of the 
earliest changes that occur in HD pathogenesis prior to dis-
ease onset.
Multiple lines of evidence highlight the importance of exon 
1 HTT in the pathogenesis of HD,3,5,32 and a mechanism for 
generation of mutant exon 1 HTT has been demonstrated in 
mouse models7 and patient-derived fibroblasts and post-mor-
tem human brain tissue.8 Whilst some cell models have demon-
strated rapid onset of cell toxicity and cell death on expression 
of exon 1 mutant HTT,9,11,33 many others do not.34,35 For exam-
ple, a study by Kim et al 2016 also did not find any overt cell 
death at baseline in an exon 1 HTT cell model as assessed by 
F I G U R E  5  Mitochondrial respiratory function is compromised in the ReNcell VM 122 CAG line. The following respiratory parameters 
were calculated from OCR measurements obtained during Seahorse XF Mito Stress Tests for both NSC and DD7 neurons: A, Basal respiration. B, 
ATP production. C, Maximal respiration. D, Non-mitochondrial respiration. E, Proton leak, and F, Coupling efficiency. Means were taken from 
three independent experiments (10 technical replicates per line, per experiment) and normalized to the 30 CAG control line readouts, (*P < .05, 
**P < .01). Data are shown as mean ± SEM
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LDH assay and MTT assay, despite finding polyQ-length-de-
pendent changes in protein interactions.35 The recapitulation 
of the inclusion formation that is pathognomic of HD confirms 
our model's validity as an HD cell model.
Many neurodegenerative diseases have protein aggregates 
as a cardinal feature, for example amyloid inclusions derived 
from amyloid precursor protein in Alzheimer's disease and 
alpha-synuclein in Parkinson's disease. In HD, mutant HTT 
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positive inclusions are found in the nuclei and neurites of patient 
derived brain tissue.3 Inclusion frequency and rate of formation 
are polyQ length-dependent and inclusion size increases with 
disease duration,36,37 as also demonstrated by our model sys-
tem. The definitive role of these inclusions (whether toxic or 
protective) has not yet been established. Toxicity is suggested 
F I G U R E  6  Electron transport chain defects in ReNcell VM 122 CAG neurons. A, The activities of complex I and II + III are significantly 
reduced in the 122 CAG line (*P < .05) but complex IV was unaffected compared across all lines at DD14. To further pinpoint the defect in 
mitochondrial respiration, the 30 CAG and 122 CAG lines were assayed for complex II and III and B, CoQ10 status. CoQ10 status is expressed as 
pmol/mg divided by CS activity. No significant difference was found in complex II activity or the electron carrier CoQ10, but a significant reduction in 
complex III activity was detected in the 122 CAG neurons (*P < .05). All complex activities are normalized to CS activity to correct for mitochondrial 
enrichment of the samples, and normalized for total protein. Means were calculated for three samples generated from three independent differentiations 
per line. Data are shown as mean ± SEM. C, The relative levels of mitochondrial complex subunits were measured by Western blotting of labile 
subunits from complexes I-V (green) vs GAPDH (red). D, Quantification of expression levels of individual complex subunits shown in C by band 
densitometry, normalized to GAPDH. No significant differences in expression were found. Data are shown as mean ± SEM
F I G U R E  7  Mitochondrial morphology in ReNcell VM 122 CAG neurons. A, Maximum intensity projection images of z-stacks taken during 
live imaging of exon 1 HTT neurons following pre-incubation with TMRM (red). GFP expression is also visualized (green). Mitochondria appear 
aggregated and dysmorphic in 122 CAG cells, compared with the reticular appearance of mitochondria in 30 CAG cells (yellow arrows). Scale 
bar = 20 µm. B, There is a trend towards a reduced basal Ψm in 71 CAG cells as measured by confocal live imaging with TMRM but not in the 
122 CAG line. Mean intensities per unit volume were calculated from 3 to 4 non-overlapping FOVs from three independent cultures per line, and 
calculated as a percentage of control (30 CAG). Data are shown as mean ± SEM. C, Individual mitochondria detected within cells were classified 
as small (<100 µm3), medium (100-1000 µm3), or large (>1000 µm3), and the sum of all mitochondrial volumes within each category expressed as 
a percentage of total mitochondrial volume. There is an apparent reduction in the proportion of small mitochondria and increase in proportion of 
medium-sized mitochondrial puncta in 122 CAG neurons. D, Quantification of OPA1 isoforms by band densitometry of the Western blot from 30 
CAG and 122 CAG DD14 samples showed no significant difference in expression of long-form, short-form, or total OPA1 normalized to GAPDH, 
or the ratio of long and short forms. Data are shown as mean ± SEM
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by experiments showing that the reduction of aggregate forma-
tion in mice correlated with improvements in phenotype.38,39 
Inclusions are thought to sequester and decrease levels of es-
sential cellular proteins such as transcription factors,40 chap-
erones,41 and nuclear-cytoplasmic transport machinery,42 and 
mutant HTT aggregates can also physically obstruct subcellu-
lar transport due to their large size.43 The toxic effects of mu-
tant HTT aggregates may cause neuronal dysfunction without 
necessarily leading to cell death and distinct structural forms 
of HTT aggregates may differ in terms of their relative con-
tribution to cell toxicity.44 In our model system, the presence 
of IB formation was not associated with cell death and those 
cells with inclusion-containing nuclei did not display abnormal 
shaped or fragmented nuclei, even though they were signifi-
cantly larger. It was not possible to measure total cytoplasmic 
area of IB-containing cells due to the complex and overlap-
ping nature of neuronal cultures, but this may also have been 
compromised and warrants further investigation. By way of 
explanation, it is possible that the increased nuclear size in the 
IB containing cells is a spatial effect of the inclusions them-
selves, or may be due to an osmotic effect, drawing water into 
the nuclei and expanding their size. This may lead in turn to 
impaired cell function, including aspects of the transcriptional 
dysregulation that is known to occur in HD, or due to disrupted 
nucleocytoplasmic transport.45 Instead, we observed that cells 
with inclusions frequently showed reduced staining intensity 
of cell markers in the perinuclear region, potentially reflective 
of transcriptional downregulation at least of these genes. This 
is supported by recent findings showing that the formation of 
HTT IBs triggers a state of cellular quiescence, as a result of 
co-aggregation with other proteins.46
Cellular respiratory deficits have been reported previously 
in HD cell models, including primary cultures derived from 
mouse R6/2 and rat BACHD models,47-50 but the effects were 
inconsistent. Other reports using the methods outlined here 
show no differences in OCR or ATP production in isolated 
rodent neurons.51 Data obtained so far from human (HD pa-
tient-derived) cells, however, have consistently shown im-
paired respiration compared with controls.52,53 Our aim in 
assessing the respiratory function of exon 1 HTT expressing 
human neuronal cells was to help resolve whether respiratory 
impairment is a feature of mutant HTT cytotoxicity. Our find-
ings are in line with previous reports of impaired basal respira-
tion, maximal respiration, and ATP production in human HD 
cell models. Furthermore, this toxic effect can be attributed to 
the mutant exon 1 HTT fragment, which exerts its patholog-
ical effect at higher polyQ lengths, even in neural stem cells, 
and is not restricted to those cells in which nuclear inclusions 
have formed. In fact, as the percentage of cells which go on to 
develop detectable aggregates is very small, these cells could 
not by any reasonable assumption be contributing to the over-
all mitochondrial impairment of the cultures seen in neurons, 
thereby the mutant exon 1 HTT-dependent effect on respiration 
and ATP levels must be attributable to HTT not present in nu-
clear aggregates. Reduced levels and/or activity of electron 
transport chain components is a well-known phenomenon in 
HD.28 Again, we confirm this significant biochemical defect 
in our cell model; specifically the reduction of in vitro enzy-
matic activity of complex I and III in exon 1 HTT 122 CAG 
neurons, with a clear effect of increasing CAG length on elec-
tron transport chain impairment. Our model demonstrates that 
the exon 1 HTT fragment is sufficient to cause mitochondrial 
dysfunction, by a mechanism that is incompletely defined but 
likely is not via altered expression of respiratory chain com-
plexes. The primary knock-on effects of respiratory chain 
dysfunction are arguably reduced ATP production, which in 
turn will affect an array of intracellular metabolic processes, 
but for neurons with an exceptionally high metabolic demand, 
even small reductions in ATP availability could contribute to 
compromised functionality, for example, in ionic homeosta-
sis and resultant excitotoxicity.54,55 The altered morphology 
of mitochondria within our HD lines was notable and could 
represent either an imbalance of fusion-fission dynamics or 
disrupted organellar transport. Mitochondrial dysmorphology 
and increased fission is increasingly being reported in HD 
models.56 We did not find any significant alteration in the ex-
pression levels of long or short isoforms of the GTPase OPA1 
in the HD lines tested, suggesting this was not due to disrup-
tion to pro-fusion components.
Studying in vitro cell models of HD is critical for understand-
ing of cell-level effects of mutant HTT on individual cell func-
tion and behaviour that is difficult to study in whole organisms. 
Due to the ongoing, urgent need to develop novel therapeutics 
for HD, there is also demand for robust cellular models for 
high throughput screening of pre-clinical compounds. Models 
expressing full-length mutant HTT may more closely reflect 
the actual cellular physiology of HD, but N-terminal or exon 1 
models give rise to disease phenotypes, for example inclusion 
formation, on a time-scale more compatible with in vitro ex-
periments. Our model is from a human source (HD is a disease 
that affects only humans), and reflects the primary site of pa-
thology in HD (neurons). On a practical level, pluripotent stem 
cell-derived neurons take weeks or months to generate, and so 
far have generally not recapitulated the inclusion pathology that 
is characteristic of HD.57 Neurons derived from human em-
bryonic stem cells (hESCs) expressing the mutant HTT exon 
1 transgene (Q73 and Q145) display HTT inclusions only after 
several months.58 Our “intermediate model” has the benefits, 
as demonstrated here, of accelerated pathology, ease of rapid 
differentiation, quick turnover time, and amenability to high 
throughput formats that are useful in a screening context.
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